Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01688401 : Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
PhasePhase 1
AgesMin: 1 Month Max: 17 Years
Eligibility
Inclusion Criteria:

- Pediatric patients of all ages with progressive DIPG.

- Consensus following presentation of the case at the multidisciplinary Pediatric
Neuro-Oncology conference, which includes participation of neuro-oncology,
neurosurgery, radiation oncology, interventional neuroradiology and neurology.

Exclusion Criteria:

- Documented hypercoagulable disorders or vasculopathies

- INR value more than a Grade 1 toxicity by CTCAE v 4.0 criteria (>1 - 1.5 x ULN;
>1 - 1.5 times above baseline if on anticoagulation).

- APTT value more than a Grade 1 toxicity by CTCAE v 4.0 criteria (>ULN - 1.5 x
ULN).

- Platelets less than 50 x 103/mm3

- Absolute neutrophil count less than 500/ mm3

- Pregnancy

- Documented severe allergic reaction to IV iodinated contrast, specifically
bronchospasm and anaphylaxis.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01688401      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740